Acyclovir and transmission of HIV-1 from persons Infected with HIV-1 and HSV-2

View/Open
Date
2010
Author
Celum, C.
Wald, A.
Lingappa, J.R.
Magaret, A.S.
Wang, R.S.
Mugo, N.
Mujugira, A.
Baeten, J.M.
Mullins, J.I.
Hughes, J.P.
Bukusi, EA
Cohen, C.R.
Katabira, E.
Ronald, A.
Kiarie, J
Farquhar, C.
Stewart, G.J.
Makhema, J.
Essex, M.
Were, E.
Fife, K.H.
Bruyn, G. de
Gray, G.E.
McIntyre, J.A.
Manongi, R.
Kapiga, S.
Coetzee, D.
Allen, S.
Inambao, M.
Kayitenkore, K.
Karita, E.
Kanweka, W.
Delany, S.
Rees, H.
Vwalika, B.
Stevens, W.
Campbell, M.S.
Thomas, K.K.
Coombs, R.W.
Morrow, R.
Whittington, W.L.H.
McElrath, M.J.
Barnes, L.
Ridzon, R.
Corey, L.
Type
Article
Language
en
Metadata
Show full item record

Abstract
Most persons who are infected with human immunodeficiency virus type 1 (HIV-1) are also infected with herpes simplex virus type 2 (HSV-2), which is frequently reactivated and is associated with increased plasma and genital levels of HIV-1. Therapy to suppress HSV-2 reduces the frequency of reactivation of HSV-2 as well as HIV-1 levels, suggesting that suppression of HSV-2 may reduce the risk of transmission of HIV Daily acyclovir therapy did not reduce the risk of transmission of HIV-1, despite a reduction in plasma HIV-1 RNA of 0.25 log10 copies per milliliter and a 73% reduction in the occurrence of genital ulcers due to HSV-2. (ClinicalTrials.gov number, NCT00194519
URI
http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/12229
Citation
The new england journal of medicine
Collections